Joseph Scarrott
PhD
Neuroscience, School of Medicine and Population Health
Process Development Scientist
- Research interests
-
Gene Therapy
Viral Vector Development
Viral Vector Manufacturing
- Publications
-
Journal articles
- Molecular design of controllable recombinant adeno‐associated virus (AAV) expression systems for enhanced vector production. Biotechnology Journal, 19(6). View this article in WRRO
- Ap4b1-knockout mouse model of hereditary spastic paraplegia type 47 displays motor dysfunction, aberrant brain morphology and ATG9A mislocalization. Brain Communications, 5(1).
- Increased recombinant adeno‐associated virus production by HEK293 cells using small molecule chemical additives. Biotechnology Journal.
- Engineering of the CMV promoter for controlled expression of recombinant genes in HEK293 cells. Biotechnology Journal, 17(8).
- Production of trimeric SARS‐CoV‐2 spike protein by CHO cells for serological COVID‐19 testing. Biotechnology and Bioengineering, 118(2), 1013-1021. View this article in WRRO
- Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking. Human Molecular Genetics, 29(2), 320-334.
- Translating SOD1 gene silencing towards the clinic: A highly efficacious, off-target free and biomarker-supported strategy for familial ALS. Molecular Therapy : Nucleic Acids, 12, 75-88. View this article in WRRO
- Current developments in gene therapy for amyotrophic lateral sclerosis.. Expert Opinion on Biological Therapy. View this article in WRRO
- Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47. EMBO Molecular Medicine.
Chapters
- Gene Therapy in the Nervous System: Failures and Successes In El-Khamisy S (Ed.), Personalised Medicine Lessons from Neurodegeneration to Cancer Springer
- Gene Therapy in the Nervous System: Failures and Successes, Personalised Medicine (pp. 241-257). View this article in WRRO
Conference proceedings papers
- Small molecule chemical additives for enhanced recombinant AAV production in HEK293 cells. HUMAN GENE THERAPY, Vol. 33(23-24) (pp A105-A105)
- Development of an AAV9-mediated gene therapy for hereditary spastic paraplegia 47. HUMAN GENE THERAPY, Vol. 30(8) (pp A18-A18)
Patents
Preprints
- Increased recombinant AAV production by HEK293 cells using small molecule chemical additives, Authorea, Inc..
- Production of Trimeric SARS-CoV-2 Spike Protein by CHO Cells for Serological COVID-19 Testing, Cold Spring Harbor Laboratory.
- Production of Trimeric SARS-CoV-2 Spike Protein by CHO Cells for Serological COVID-19 Testing, Authorea, Inc..
- Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay, Cold Spring Harbor Laboratory.